Novavax’s candidate protein-based vaccine has been more than 93% effective against the dominant strains of the new coronavirus, which are described as variants of concern to scientists and public health officials, according to Novavax.
The survey, which involved nearly 30,000 volunteers in the United States and Mexico, puts Novavax well on track to apply for emergency vaccine approval in the United States and elsewhere in the third quarter of 2021, according to the company. .
During the test, the B.1.1.7 mutant, first identified in Britain, became the most common mutant of the new coronavirus in the United States, she added.
Novavax also identified variant strains of COVID-19 that were first identified in Brazil, South Africa and India among the test participants, Novavax’s head of research and development Gregory Glenn told Reuters.